Why We Should Treat COVID-19 Long-Hauler Syndromes with Convalescent Plasma; Contained Suppressive Exosomes Are Likely COVID Antigen-Specific

    January 2024 in “ Authorea (Authorea) ”
    P. W. Askenase

    Preprint — not peer reviewed. This was posted to a preprint server or data repository. It has not been through a journal's review process, and its findings may change or not hold up.

    Studysummary This source suggests that convalescent plasma therapy may interfere with early immune responses in COVID-19 due to exosomes suppressing immune cell activity, but proposes it could potentially help with COVID-19 Long Hauler Syndromes by targeting diverse antigen responses beyond just the spike protein.
    Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
    Read the full study on authorea.com →
    Discuss this study in the Community →